Remote Monitoring with TDtect for Tardive Dyskinesia

Recruiting at 1 trial location

Overseen By Owen Muir, M.D.

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: iRxReminder

Must be taking: Antipsychotics

Disqualifiers: Head injury, Learning disorder, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

300 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if Tardive Dyskinesia (TD), a movement disorder often caused by long-term use of antipsychotic medication, can be assessed remotely using a tool called TDtect (a remote monitoring device). Researchers seek to establish the reliability of this method for individuals with and without TD who are taking antipsychotic medications. Those who have been on antipsychotic drugs for at least 90 days and do not have a movement disorder from other conditions like Parkinson's might be suitable candidates. The trial evaluates the effectiveness of remote monitoring in these scenarios. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could enhance remote monitoring for TD patients.

Do I have to stop taking my current medications for the trial?

The trial does not specify if you need to stop taking your current medications. However, if you are in the non-TD group, you must have been taking an antipsychotic medication for at least 90 days.

What prior data suggests that TDtect is safe for remote monitoring of Tardive Dyskinesia?

Research shows that TDtect is being tested for its safety and effectiveness in remotely monitoring Tardive Dyskinesia, a movement disorder. Earlier studies found this video-based method reliable in detecting Tardive Dyskinesia. However, specific information about side effects from these studies is unavailable. Since this study focuses on the effectiveness of remote monitoring, it does not involve testing a new drug or performing invasive procedures. This typically means fewer risks, but prospective participants should stay informed and ask questions before joining. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the Remote Monitoring with TDtect for Tardive Dyskinesia trial because it explores innovative ways to manage this condition through technology. Current treatments for Tardive Dyskinesia often involve medications like tetrabenazine or deutetrabenazine, which aim to reduce symptoms but can have significant side effects and require regular monitoring by healthcare professionals. TDtect offers a unique approach by utilizing remote monitoring technology, potentially allowing for continuous observation and management of symptoms without frequent in-person visits. This method could provide patients with more consistent care and improve quality of life by quickly adapting treatment plans based on real-time data. The hope is that this approach will lead to more personalized and effective care for individuals dealing with Tardive Dyskinesia.

What evidence suggests that TDtect is effective for remote monitoring of Tardive Dyskinesia?

Research has shown that Tardive Dyskinesia (TD) involves movement problems often caused by long-term use of certain medications. In this trial, TDtect aims to help manage these issues. Although specific data on TDtect's effectiveness is not yet available, similar treatments for TD have shown promise. Many patients using these treatments report satisfaction and symptom relief. This suggests that TDtect could potentially manage TD symptoms effectively. ^{6 7 8 9 10}

Who Is on the Research Team?

Rakesh Ranjan, M.D.

Principal Investigator

Charak Research Center

Owen Muir, M.D.

Principal Investigator

Fermata Health

Are You a Good Fit for This Trial?

This trial is for English-speaking individuals who have been on antipsychotic medication for at least 90 days. It's not suitable for those with Tardive Dyskinesia symptoms from Parkinson's, Tourette's, or Huntington disease. Participants must consent to the study and cannot have had a severe head injury in the past year, learning disorders that affect protocol adherence, or uncorrectable severe visual impairment.

Inclusion Criteria

For the non-TD group: Speaks English fluently

You have been taking antipsychotic medication for 90 days or more.

If you have symptoms of Tardive Dyskinesia, they are not caused by Parkinson's, Tourette's syndrome, or Huntington's disease.

Exclusion Criteria

You had a serious head injury in the past year.

History of a learning disorder or developmental disability that would inhibit a patient from completing the TD protocol

You have very poor vision that cannot be fixed with glasses or contacts.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Remote Monitoring

Participants are remotely assessed for Tardive Dyskinesia using video recordings and interviews

4-6 weeks

Remote assessments

Follow-up

Participants are monitored for safety and effectiveness after remote monitoring

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• TDtect

Trial Overview

The trial is testing 'TDtect', a method for remotely monitoring and assessing Tardive Dyskinesia—a movement disorder caused by long-term use of certain medications. The goal is to see if this tool can effectively evaluate patients outside of a clinical setting.

How Is the Trial Designed?

Group I: Taking antipsychotic medication without Tardive Dyskinesia Experimental Treatment 1 Intervention

Group II: Taking antipsychotic medication with Tardive Dyskinesia Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

iRxReminder

Lead Sponsor

Trials

1

Recruited

300+

National Institute of Mental Health (NIMH)

Collaborator

Trials

3,007

Recruited

2,852,000+

Citations

1.

uspharmacist.com

uspharmacist.com/article/study-explores-tardive-dyskinesia-outcomes-with-deutetrabenazine-use

Study Explores Tardive Dyskinesia Outcomes With ...

In this interim analysis of data from 131 respondents, results revealed that 87% reported satisfaction with the medication overall, and 74% ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10732123/

Exploring real-world symptom impact and improvement in well ...

Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via ...

3.

ncbi.nlm.nih.gov

ncbi.nlm.nih.gov/books/NBK448207/

Tardive Dyskinesia - StatPearls - NCBI Bookshelf

Tardive dyskinesia is a syndrome that includes a group of iatrogenic movement disorders caused by the blockade of dopamine receptors.

4.

icer.org

icer.org/wp-content/uploads/2020/10/Atlas-2019_TD.pdf

Effectiveness and Value of 2 Novel Treatments for Tardive ...

Dyskinesia: Effectiveness and Value (Final Evidence ... Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.

5.

pharmacytimes.com

pharmacytimes.com/view/movement-scores-and-beyond-patient-reported-outcomes-in-tardive-dyskinesia-management

Patient-Reported Outcomes in Tardive Dyskinesia ...

This patient-focused approach helps capture how TD affects daily physical functioning—such as pain, difficulty chewing or swallowing, walking, ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06011408

Remote Monitoring and Detecting of Tardive Dyskinesia for ...

The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia. Participants will all be taking an antipsychotic medication ...

7.

psychiatrist.com

psychiatrist.com/wp-content/uploads/2025/05/detecting-tardive-dyskinesia-using-video-based-artificial-intelligence-25m15792.pdf

detecting-tardive-dyskinesia-using-video-based-artificial- ...

This study demonstrates a novel, efficient, and reliable method to detect and bring TD to psychiatrists' attention using video-based artificial.

8.

withpower.com

withpower.com/trial/phase-dyskinesias-4-2023-4c2bf

Remote Monitoring with TDtect for Tardive Dyskinesia

This N/A medical study run by iRxReminder is evaluating whether TDtect will have tolerable side effects & efficacy for patients with Tardive Dyskinesia and ...

9.

reporter.nih.gov

reporter.nih.gov/project-details/10800790

Remote Monitoring and Detecting of Tardive Dyskinesia for ...

Abstract - Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes Tardive dyskinesia (TDD) is a common debilitating side effect ...

10.

psychiatrist.com

psychiatrist.com/jcp/detecting-tardive-dyskinesia-using-video-based-artificial-intelligence/

Detecting Tardive Dyskinesia Using Video-Based Artificial ...

This study demonstrates a novel, efficient, and reliable method to detect and bring TD to psychiatrists' attention using video-based artificial intelligence.